Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEquity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income - MinorityNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeTax ProvisionsTax Rate
Others
Ratios

Pharming (PHAR) Consolidated Net Income (2020 - 2025)

Historic Consolidated Net Income for Pharming (PHAR) over the last 6 years, with Q3 2025 value amounting to $25.0 million.

  • Pharming's Consolidated Net Income rose 27524.04% to $25.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $24.4 million, marking a year-over-year increase of 15647.29%. This contributed to the annual value of -$12.0 million for FY2024, which is 20512.36% down from last year.
  • Per Pharming's latest filing, its Consolidated Net Income stood at $25.0 million for Q3 2025, which was up 27524.04% from $9.4 million recorded in Q2 2025.
  • Pharming's 5-year Consolidated Net Income high stood at $25.6 million for Q2 2021, and its period low was -$22.5 million during Q2 2024.
  • Moreover, its 5-year median value for Consolidated Net Income was $884013.0 (2021), whereas its average is $378790.3.
  • Per our database at Business Quant, Pharming's Consolidated Net Income plummeted by 28390.75% in 2021 and then soared by 2476194.35% in 2022.
  • Quarter analysis of 5 years shows Pharming's Consolidated Net Income stood at $15.2 million in 2021, then plummeted by 210.61% to -$16.8 million in 2022, then soared by 59.22% to -$6.9 million in 2023, then rose by 10.86% to -$6.1 million in 2024, then surged by 508.97% to $25.0 million in 2025.
  • Its Consolidated Net Income stands at $25.0 million for Q3 2025, versus $9.4 million for Q2 2025 and -$3.9 million for Q1 2025.